Successful post-exposure prophylaxis of Ebola infected non-human primates using Ebola glycoprotein-specific equine IgG.
Herein we describe production of purified equine IgG obtained from horses immunized with plasmid DNA followed by boosting with Kunjin replicon virus-like particles both encoding a modified Ebola glycoprotein. Administration of the equine IgG over 5 days to cynomolgus macaques infected 24 hours previously with a lethal dose of Ebola virus suppressed viral loads by more than 5 logs and protected animals from mortality. Animals generated their own Ebola glycoprotein-specific IgG responses 9-15 days after infection, with circulating virus undetectable by day 15-17. Such equine IgG may find utility as a post-exposure prophylactic for Ebola infection and provides a low cost, scalable alternative to monoclonal antibodies, with extensive human safety data and WHO-standardized international manufacturing capability available in both high and low income countries.
State Center for Virology and Biotechnology Vector, Koltsovo, Russian Federation.
Oleg V
OV
Pyankov
Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Brisbane, QLD, Australia.
Yin Xiang
YX
Setoh
State Center for Virology and Biotechnology Vector, Koltsovo, Russian Federation.
Sergey A
SA
Bodnev
Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Brisbane, QLD, Australia.
Judith H
JH
Edmonds
State Center for Virology and Biotechnology Vector, Koltsovo, Russian Federation.
Olga G
OG
Pyankova
State Center for Virology and Biotechnology Vector, Koltsovo, Russian Federation.
Stepan A
SA
Pyankov
Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Brisbane, QLD, Australia.
Gabor
G
Pali
Plasvacc Pty. Ltd., Kalbar, QLD, Australia.
Shane
S
Belford
Bio Medical Manufacturing, Fermentation and Protein Production Facility, CSIRO, Clayton, VIC, Australia.
Louis
L
Lu
Bio Medical Manufacturing, Fermentation and Protein Production Facility, CSIRO, Clayton, VIC, Australia.
Mylinh
M
La
Bio Medical Manufacturing, Fermentation and Protein Production Facility, CSIRO, Clayton, VIC, Australia.
George
G
Lovrecz
Molecular Basis of Viral Pathogenicity, CIRI, INSERM, U1111-CNRS UMR5308, Université de Lyon, Université Claude Bernard Lyon 1, Ecole Normale Supérieure de Lyon, France.
Valentina A
VA
Volchkova
Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Brisbane, QLD, Australia.
Keith J
KJ
Chappell
Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Brisbane, QLD, Australia.
Daniel
D
Watterson
Australian Animal Health Laboratory, CSIRO Health and Biosecurity, Geelong, VIC, Australia.
Glenn
G
Marsh
Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Brisbane, QLD, Australia.
Paul R
PR
Young
State Center for Virology and Biotechnology Vector, Koltsovo, Russian Federation.
Alexander A
AA
Agafonov
United Nations Medical Service, New York, NY 10017, USA.
Jillann F
JF
Farmer
Molecular Basis of Viral Pathogenicity, CIRI, INSERM, U1111-CNRS UMR5308, Université de Lyon, Université Claude Bernard Lyon 1, Ecole Normale Supérieure de Lyon, France.
Victor E
VE
Volchkov
QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Andreas
A
Suhrbier
Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Brisbane, QLD, Australia.
Alexander A
AA
Khromykh
D000818:Animals; D057134:Antibodies, Neutralizing / Q000276:immunology; D000914:Antibodies, Viral / Q000008:administration & dosage* / Q000276:immunology / Q000302:isolation & purification; D000918:Antibody Specificity / Q000276:immunology; D000956:Antigens, Viral / Q000276:immunology*; D029043:Ebolavirus / Q000276:immunology*; D006023:Glycoproteins / Q000276:immunology; D019142:Hemorrhagic Fever, Ebola / Q000276:immunology* / Q000517:prevention & control*; D006736:Horses; D007074:Immunoglobulin G / Q000008:administration & dosage* / Q000276:immunology / Q000302:isolation & purification; D008252:Macaca fascicularis; D056990:Post-Exposure Prophylaxis
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D000956:Antigens, Viral; D006023:Glycoproteins; D007074:Immunoglobulin G